Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2016 now is available at the company’s website: www.medivir.com.
- We implemented several measures in 2016 to achieve a more streamlined and efficient Medivir. One key step in this process was the shift to a dedicated focus on research and development, resulting in the sale of BioPhausia, the company that handled the commercial sales of our pharmaceuticals in the Nordic region. This move generated concrete value for our shareholders in the form of a resolution at an EGM after the end of the financial year to disburse the net proceeds of the sale in the form of a voluntary redemption offer. We also decided that our R&D would focus exclusively on oncology, i.e. cancer, and to this end, acquired two interesting late clinical phase oncology projects, remetinostat and birinapant. I am, however, convinced that the extensive transformation we completed in 2016 has laid an excellent foundation for Medivir’s future development. Our strong and balanced R&D portfolio – based on our scientific platforms in the areas of protease inhibitors and nucleosides/nucleotides – offers huge potential for building value in both the short and long-term. It is, therefore, with a sense of pride and great confidence, that I can state that now is the right time to hand over the baton to a new CEO, Christine Lind, said Medivir’s former CEO, Niklas Prager, in his CEO’s Statement in this year’s Annual Report.
For further information, please contact:
Ola Burmark, CFO Medivir AB, mobil: +46 (0)725-480 580.
About Medivir
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.